{"id":"NCT03561883","sponsor":"Ironwood Pharmaceuticals, Inc.","briefTitle":"Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-06","primaryCompletion":"2020-07-28","completion":"2020-11-06","firstPosted":"2018-06-19","resultsPosted":"2021-08-18","lastUpdate":"2021-08-18"},"enrollment":609,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"interventions":[{"type":"DRUG","name":"IW-3718","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"Standard-dose PPIs QD","otherNames":[]}],"arms":[{"label":"1500 mg IW-3718 BID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.","primaryOutcome":{"measure":"Change From Baseline in WHSS at Week 8","timeFrame":"Baseline, Week 8","effectByArm":[{"arm":"Placebo BID + PPIs","deltaMin":-1.751,"sd":0.081},{"arm":"1500 mg IW-3718 BID + PPIs","deltaMin":-1.814,"sd":0.082}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5566"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":101,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":304},"commonTop":["Constipation","Nausea"]}}